Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham speaks with Proactive after raising A$13 million in a placement of shares to a small consortium of US and international institutional investors with significant healthcare experience in the US, Europe and Asia. The funds will be used for research and development of the company’s drug candidates, including the candidates acquired as part of the acquisition of APIRx Pharmaceuticals.
Incannex Healthcare discusses A$13 million institutional placement
